# Clinical Cases: Enzyme Kinetics and Regulation

## Case 1: Acute Pancreatitis (Zymogen Premature Activation)

### Clinical Image
![Acute Pancreatitis CT](case_01_image.jpg)
*Source: [Radiopaedia - Acute pancreatitis](https://radiopaedia.org/cases/acute-pancreatitis-ct-1) - CC BY-NC-SA 3.0*

### Case Presentation
A 45-year-old man with a history of heavy alcohol use presents to the emergency department with severe epigastric pain radiating to his back, accompanied by nausea and vomiting for the past 12 hours. The pain is constant, worse when lying flat, and partially relieved by leaning forward. Physical examination reveals epigastric tenderness with guarding. Vital signs show temperature 38.1C, heart rate 105, blood pressure 140/90, and respiratory rate 20. Laboratory studies reveal markedly elevated serum lipase at 1,850 U/L (normal <60) and amylase at 1,200 U/L (normal <100). Serum triglycerides are normal and there is no biliary dilation on ultrasound, suggesting alcohol as the etiology. CT scan with contrast shows diffuse pancreatic enlargement with peripancreatic fat stranding and small fluid collections consistent with acute interstitial edematous pancreatitis. The patient is admitted for IV fluid resuscitation, pain control, and bowel rest. He is counseled on alcohol cessation as the key to preventing recurrence.

### Key Learning Points
- Acute pancreatitis results from premature intrapancreatic activation of digestive enzyme zymogens (particularly trypsinogen to trypsin), causing autodigestion of pancreatic tissue
- Normally, protective mechanisms prevent zymogen activation until they reach the small intestine: trypsinogen is activated by enterokinase in the duodenum, which then activates other zymogens in an amplifying cascade
- Serum lipase and amylase are elevated because cellular injury releases these enzymes into the bloodstream; lipase is more specific for pancreatic injury

---

## Case 2: Statin Therapy for Hypercholesterolemia (Competitive Enzyme Inhibition)

### Clinical Image
![Statin Structure](case_02_image.jpg)
*Source: [Wikipedia - Statin](https://en.wikipedia.org/wiki/Statin) - Public Domain*

### Case Presentation
A 58-year-old woman with type 2 diabetes and hypertension presents for routine follow-up. Her fasting lipid panel reveals LDL cholesterol of 168 mg/dL (goal <70 for her risk profile), HDL 42 mg/dL, and triglycerides 180 mg/dL. She has a 10-year ASCVD risk score of 22%. After discussing lifestyle modifications including diet and exercise, she is started on atorvastatin 40 mg daily. At her 6-week follow-up, repeat lipid panel shows LDL cholesterol reduced to 85 mg/dL, a 49% reduction. She reports mild muscle aches that improve with continued use. She is counseled that statins competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Because the inhibition is competitive, endogenous substrate (HMG-CoA) can still bind when inhibitor concentrations fall between doses, which is why consistent daily dosing is important. She tolerates therapy well and continues on this regimen.

### Key Learning Points
- Statins are competitive inhibitors of HMG-CoA reductase that structurally resemble the enzyme's transition state intermediate
- Competitive inhibition increases apparent Km (more substrate needed to reach half-maximal velocity) but does not change Vmax (maximum velocity can still be achieved with sufficient substrate)
- On a Lineweaver-Burk plot, competitive inhibitors produce lines that intersect on the y-axis, reflecting unchanged Vmax but increased Km

---

## Case 3: Organophosphate Poisoning (Irreversible Enzyme Inhibition)

### Clinical Image
![Organophosphate Mechanism](case_03_image.jpg)
*Source: [Wikipedia - Organophosphate poisoning](https://en.wikipedia.org/wiki/Organophosphate_poisoning) - CC BY-SA 4.0*

### Case Presentation
A 32-year-old agricultural worker is brought to the emergency department after being found confused and salivating excessively in a field where pesticides were recently applied. His coworkers noted he was not wearing protective equipment. On examination, he has pinpoint pupils (miosis), profuse sweating, excessive salivation and lacrimation, bronchorrhea with audible wheezing, bradycardia (heart rate 48), and fasciculations of facial and limb muscles. He is also incontinent of urine. These findings represent the classic cholinergic toxidrome (SLUDGE/BBB: Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis, Bradycardia, Bronchospasm, Bronchorrhea). He is immediately treated with IV atropine to block muscarinic effects and pralidoxime (2-PAM) to reactivate acetylcholinesterase before irreversible "aging" of the enzyme occurs. Pralidoxime must be given within hours because after aging, the organophosphate-enzyme bond becomes permanent and no antidote can restore function. The patient improves over 48 hours with supportive care.

### Key Learning Points
- Organophosphate pesticides and nerve agents are irreversible inhibitors of acetylcholinesterase, covalently phosphorylating the active site serine residue
- Unlike reversible inhibitors, irreversible inhibitors permanently inactivate enzymes; recovery requires synthesis of new enzyme molecules
- Pralidoxime can reactivate the enzyme only before "aging" (dealkylation of the organophosphate-enzyme complex), which occurs within hours; this time-sensitive treatment illustrates the clinical importance of understanding enzyme inhibition kinetics